[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
February 19, 2014

Treatment of Lower Extremity Superficial Thrombophlebitis

Author Affiliations
  • 1Department of Medical, Oral, and Biotechnological Sciences, Università “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy
  • 2Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
JAMA. 2014;311(7):729-730. doi:10.1001/jama.2014.520
Abstract

Clinical Question  What treatments for lower extremity superficial thrombophlebitis are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superficial venous thrombosis extension?

Bottom Line  Fondaparinux (2.5 mg) subcutaneously once daily for 45 days is associated with fewer symptomatic VTEs and lower rates of superficial venous thrombosis extension and recurrence with no increases in major bleeding compared with placebo. Low-molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with lower rates of superficial thrombophlebitis extension or recurrence, but data regarding symptomatic VTEs are inconclusive.

×